Who Qualifies for the Medicare GLP-1 Bridge? 2026 Eligibility Rules

To qualify for the Medicare GLP-1 Bridge, you need two things at once: the right kind of Medicare coverage and a qualifying clinical profile. Specifically, you must be enrolled in a standalone Part D drug plan or a Medicare Advantage plan that includes drug coverage, and you must meet one of three BMI-and-condition tiers measured at the start of your GLP-1 treatment. There’s also a rule that quietly disqualifies a lot of people: if you already get a GLP-1 through Part D for another condition, you can’t use the Bridge for weight loss. Below is the exact breakdown so you can check yourself against it before talking to a prescriber.

The coverage requirement comes first

Before any clinical criteria matter, you need Medicare drug coverage of the right type. That means either a standalone Part D prescription drug plan or a Medicare Advantage plan that bundles drug coverage (often written as MA-PD). If you only have Original Medicare with no drug plan, the Bridge has nothing to attach to. This is the first filter, and it’s easy to overlook because people assume “having Medicare” is enough.

The three clinical tiers

If your coverage qualifies, you then need to meet one of three thresholds. These mirror the clinical logic behind GLP-1 approvals: the higher your weight-related risk, the lower the BMI needed to qualify.

Meeting any one tier is enough. You don’t need to satisfy all three.

The rule that disqualifies many people

Here’s the filter that surprises the most people. The Bridge only pays when a GLP-1 is prescribed for obesity. If you already receive a GLP-1 through your Part D plan for type 2 diabetes, for cardiovascular risk reduction, or for moderate-to-severe sleep apnea, you stay on that existing coverage and you don’t use the Bridge. The program isn’t meant to layer on top of coverage you already have.

That distinction matters because so many older adults are already on a GLP-1 for diabetes. If that’s you, your path runs through your regular Part D benefit, not the Bridge.

Timing: it’s measured at the start of treatment

Eligibility is assessed at the point your GLP-1 therapy begins, and your prescriber attests to it. This is good news if you’ve already lost weight. Consider a scenario where someone started treatment two years ago at a BMI of 37, then dropped to a BMI of 32. The prescriber can attest that the BMI was 35 or higher at initiation, which is the number that governs eligibility. You don’t lose access for succeeding.

What qualifying does and doesn’t get you

Qualifying gets you a flat $50 monthly copay on covered weight-loss GLP-1s: Wegovy in all its forms, Foundayo, and the Zepbound KwikPen specifically. It does not get you the Zepbound vials or single-dose pens, which sit outside the program. And the $50 you pay won’t count toward your deductible or out-of-pocket cap, because the Bridge runs outside the normal Part D structure.

Consider a scenario where a 70-year-old with a BMI of 31 and chronic kidney disease checks the tiers. They land in the middle tier (BMI 30 or higher with CKD), they have a Part D plan, and they aren’t already on a GLP-1. They qualify, and a covered medication will cost them $50 a month. Now change one detail: if that same person were already taking Ozempic for diabetes through Part D, they’d be disqualified from the Bridge and would continue on their diabetes coverage instead.

Why the criteria are built this way

The tiers aren’t arbitrary. They track the populations where GLP-1 benefit is best established, including people with diabetes and cardiometabolic risk. The drug-class evidence in those groups is deep. In the SUSTAIN 2 trial, once-weekly semaglutide was tested against sitagliptin over 56 weeks in adults with type 2 diabetes across 128 sites in 18 countries, and semaglutide produced superior reductions in both A1c and body weight. Trials like that, run in exactly these patient profiles, are part of why coverage rules center on weight plus metabolic conditions rather than weight alone for the lower BMI tiers.

If you don’t qualify

Plenty of people will read the tiers and realize they’re out, whether because they’re not on Medicare drug coverage, their numbers don’t reach a threshold, or they already get a GLP-1 through Part D. If that’s you, a cash-pay telehealth route doesn’t use any of these criteria. TrimRx connects you with licensed providers who prescribe semaglutide or tirzepatide when it’s clinically appropriate, and it bundles the provider visit and shipping into a flat monthly structure with no insurance required, with pricing from $179 to $1,579 depending on the medication and plan. There’s no Medicare enrollment requirement and no BMI-at-initiation attestation.

If you’re not sure whether you meet the Bridge tiers or whether a cash program makes more sense, the free assessment quiz is a quick way to find out.

This article is for general information and is not medical or insurance advice. Eligibility criteria for the Medicare GLP-1 Bridge are set by CMS and can change. Confirm your specific situation with Medicare and your prescriber before making decisions.